Evidence map›Paper›PMID 24049717›Full record

ArticleTranslational vision science & technology2013

Accelerated In Vitro Degradation of Optically Clear Low

Ke Shang, Jelena Rnjak-Kovacina, Yinan Lin, Rebecca S Hayden, Hu Tao, David L Kaplan

Open access · bronzeAbstract read
In one paragraph

Article in Translational vision science & technology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
2.9field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 44 citations in OpenAlex.

  1. Clinical progress and prospects of biodegradable intestinal stents.American journal of translational research · 2026
    Review
  2. Recent Advances in Silk Fibroin Derived fromJournal of functional biomaterials · 2025
    Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Silk-Based Therapeutics TargetingJournal of functional biomaterials · 2019
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Ke ShangDepartment of Biomedical Engineering, Tufts University, Medford, MA.
Jelena Rnjak-Kovacina
Yinan Lin
Rebecca S Hayden
Hu Tao
David L Kaplan
Tufts University · US

Funding

Translational Bioreactors - Engineering Complex TissuesP41EB002520 · NIBIB · TUFTS UNIVERSITY MEDFORD · PI KAPLAN, DAVID L. · 2004 to 2018
$16.7M
Tissue Engineering Cornea ReplacementsR01EY020856 · NEI · TUFTS UNIVERSITY MEDFORD · PI KAPLAN, DAVID L. · 2010 to 2016
$2.7M
NEI NIH HHS R01 EY020856NIBIB NIH HHS P41 EB002520
6 · The paper itself

Abstract

purposeTo design patterned, transparent silk films with fast degradation rates for the purpose of tissue engineering corneal stroma.

methods

resultsLow

conclusionsThe novel protocol developed here provides new approaches to modulate the regeneration rate of silk biomaterials for corneal tissue regeneration needs. TRANSLATIONAL RELEVANCE: Patterned silk protein films possess desirable characteristics for corneal tissue engineering, including optical transparency, biocompatibility, cell alignment, and tunable mechanical properties, but current fabrication protocols do not provide adequate degradation rates to match the regeneration properties of the human cornea. This novel processing protocol makes silk films more suitable for the construction of human corneal stroma tissue and a promising way to tune silk film degradation properties to match corneal tissue regeneration.

Indexed as

corneal tissue engineeringdegradationfilmsprotease pretreatmentsilkβ-sheet content

Identifiers

PMID24049717
PMCPMC3763893
OpenAlexW1964785923

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.